Thalidomide plays a role in the treatment of refractory CD through mediating TNF-α reduction, T-cell regulation, angiogenesis inhibition, and other (non-)immunomodulatory mechanisms (Ginsburg et al., 2001). Here, TNF is linked to Cowden disease.